Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Primary sclerosing cholangitis is a rare liver complication that can develop among people with inflammatory bowel disease. Early diagnosis can help, but there’s no cure.

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its ...

Primary sclerosing cholangitis is a rare, unpreventable liver complication that can happen among people with inflammatory bowel disease.

Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might ...

Discover a study exploring how verbal instructions and symptom expectations influence fatigue and motivation in people living with primary biliary cholangitis.

Saroglitazar has been approved in India for treating non-alcoholic fatty liver disease and its progressive form, ...

Topline data were announced from a phase 2b/3 trial evaluating saroglitazar in patients with PBC who had an inadequate response or intolerance to UDCA.

Saroglitazar is a novel peroxisome proliferator-activated receptor alpha/gamma agonist designed to target both bile acid toxicity and liver inflammation.

Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS-III trial demonstrates improved liver function in patients.